Updates

These updates includes material published by third parties and compiled by PAHO. PAHO has taken reasonable precautions to verify the information contained in the document. However, this material is being distributed without warranty of any kind. The reader is responsible for the interpretation and use of this information and in no event shall PAHO be held liable for any damages arising from its use.
  • Updates
  • Official reports from pharmacovigilance programs
  • Clarifications/conclusions of events presented in previous communications
  • Other related updates
04/27/2021

Collection of information on recently reported rare and severe events - April 2021

Use of the Janssen vaccine in the United States is temporarily suspended

Read more
03/30/2021

Vaccination and patients with long-term symptoms

There are a number of patients with COVID-19 who develop long-term symptoms after infection with SARS-CoV-2, for which the term "Long COVID" has begun to be used. The symptoms vary, but the most common are fatigue, shortness of breath, myalgia, and insomnia.

Read more
03/30/2021

Influenza-like illness after administration of COVID-19 vaccines

The Global Advisory Committee on Vaccine Safety (GACVS) of the World Health Organization (WHO) reviewed clinical trial data and a summary of reports of influenza-like illnesses following COVID-19 vaccination, drawn from the WHO Global Database of Individual Case Safety Reports (VigiBase).

Read more
03/30/2021

Use of the COVID-19 vaccination in the Region of the Americas as of 17 March 2021

Below, there is consolidated data on doses administered per 100 people in the total population, by country and total doses administered, as of 17 March 2021.

Read more
03/30/2021

Variants and impact on vaccination against COVID-19

COVID-19 vaccines (both those already developed and those in development) are based on inducing an immune response to the spicule glycoprotein (S) version of the initial pandemic SARS-CoV-2 virus.

Read more